Literature DB >> 6879487

Clinical review of pulmonary disease caused by Mycobacterium xenopi.

M J Smith, K M Citron.   

Abstract

Mycobacterium xenopi comprised 56% of all non-tuberculous mycobacteria isolated in the Brompton Hospital laboratory during six years. M xenopi alone was cultured from the sputum of 23 patients, whose clinical and bacteriological features are reviewed. Pulmonary disease was considered to be due to the organism present in 15 of these patients on the basis of strict criteria for a causal relationship. Radiographs of all these patients were consistent with mycobacterial disease, showing pulmonary cavitation in 11, apical shadowing in three, and upper lobe fibrosis in one. In nine patients the disease was chronic, progressing very slowly with longstanding respiratory symptoms and extensive radiographic abnormalities developing over many years (mean 19 years). In six patients the disease was subacute, being of recent onset with radiographic shadowing of limited extent. M xenopi was isolated as a saprophyte from four patients who had lung disease of known cause and single isolates were obtained from four patients who had no lung disease attributable to this organism. In vitro drug sensitivity tests showed the sputum cultures of 17 of 22 patients to be sensitive to two or more of the drugs rifampicin, isoniazid, and ethambutol. Response to chemotherapy was unpredictable and did not always correlate with the results of sensitivity tests. Of 11 patients treated with at least two drugs to which their organisms were sensitive, two remained sputum positive, one relapsed after 18 months of chemotherapy, and eight have remained sputum negative during a minimum of three years' follow-up.

Entities:  

Mesh:

Year:  1983        PMID: 6879487      PMCID: PMC459561          DOI: 10.1136/thx.38.5.373

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  10 in total

1.  INFECTION DUE TO MYCOBACTERIUM XENOPEI.

Authors:  J MARKS; H SCHWABACHER
Journal:  Br Med J       Date:  1965-01-02

2.  A strain of Mycobacterium isolated from skin lesions of a cold-blooded animal, Xenopus laevis, and its relation to atypical acid-fast bacilli occurring in man.

Authors:  H SCHWABACHER
Journal:  J Hyg (Lond)       Date:  1959-03

Review 3.  Nontuberculous mycobacteria and associated diseases.

Authors:  E Wolinsky
Journal:  Am Rev Respir Dis       Date:  1979-01

4.  The meaning and structure of species as applied to mycobacteria.

Authors:  J L Stanford; J M Grange
Journal:  Tubercle       Date:  1974-06

5.  M. xenopei: a bacteriological study of M. xenopei including case reports of Danish patients.

Authors:  H C Engbaek; B Vergmann; I Baess; D W Will
Journal:  Acta Pathol Microbiol Scand       Date:  1967

6.  Mycobacterium xenopei: A study of sixteen strains.

Authors:  A Beck; J L Stanford
Journal:  Tubercle       Date:  1968-06

7.  The isolation of M. kansasii and M. xenopi from water systems.

Authors:  D A McSwiggan; C H Collins
Journal:  Tubercle       Date:  1974-12

8.  Water as a source of potentially pathogenic mycobacteria.

Authors:  S Goslee; E Wolinsky
Journal:  Am Rev Respir Dis       Date:  1976-03

9.  [Mycobacterium xenopei (Marks and Schwabacher, 1965), a scotochromogenic, thermophilic, dysgonic mycobacterium, possibly pathogenic for man].

Authors:  H Boisvert
Journal:  Ann Inst Pasteur (Paris)       Date:  1965-09

10.  Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex.

Authors:  A M Hunter; I A Campbell; P A Jenkins; A P Smith
Journal:  Thorax       Date:  1981-05       Impact factor: 9.139

  10 in total
  15 in total

1.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

Review 2.  Treatment of pulmonary disease caused by opportunist mycobacteria.

Authors:  J Banks
Journal:  Thorax       Date:  1989-06       Impact factor: 9.139

3.  Clinical value of the measurement of Mycobacterium tuberculosis specific antibody in pulmonary tuberculosis.

Authors:  G H Bothamley; R Rudd; F Festenstein; J Ivanyi
Journal:  Thorax       Date:  1992-04       Impact factor: 9.139

Review 4.  Infections caused by opportunist mycobacteria: a review.

Authors:  J M Grange; M D Yates
Journal:  J R Soc Med       Date:  1986-04       Impact factor: 5.344

5.  First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.

Authors: 
Journal:  Thorax       Date:  2001-03       Impact factor: 9.139

6.  Mycobacterium xenopi isolation from clinical specimens in the Florence area: review of 46 cases.

Authors:  E Tortoli; M T Simonetti; C Labardi; A Lopes Pegna; E Meli; N Stanflin; S Susini
Journal:  Eur J Epidemiol       Date:  1991-11       Impact factor: 8.082

7.  Pulmonary disease caused by Mycobacterium xenopi: the first case in Korea.

Authors:  Hye Yun Park; Won-Jung Koh; O Jung Kwon; Nam Yong Lee; Young Mog Shim; Young Kil Park; Gill Han Bai; Ho-Suk Mun; Bum-Joon Kim
Journal:  Yonsei Med J       Date:  2007-10-31       Impact factor: 2.759

8.  Pulmonary infection with mycobacterium xenopi: review of treatment and response.

Authors:  J Banks; A M Hunter; I A Campbell; P A Jenkins; A P Smith
Journal:  Thorax       Date:  1984-05       Impact factor: 9.139

9.  Capillary gas chromatographic analysis of mycolic acid cleavage products, cellular fatty acids, and alcohols of Mycobacterium xenopi.

Authors:  M Luquin; F Lopez; V Ausina
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

10.  Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.

Authors:  Claire Andréjak; Deepak V Almeida; Sandeep Tyagi; Paul J Converse; Nicole C Ammerman; Jacques H Grosset
Journal:  J Antimicrob Chemother       Date:  2012-11-05       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.